MedTech Dive July 25, 2024
Alongside the acquisitions, Edwards reported a slowdown in its core TAVR business in the second quarter that sent its shares tumbling.
Edwards Lifesciences said Wednesday it will pay about $1.2 billion to acquire a pair of cardiac device companies that will expand its lineup of structural heart offerings.
The acquisitions come as Edwards posted weaker-than-expected second-quarter sales growth in transcatheter aortic valve replacement (TAVR), its largest business. The slowdown pressured Edwards’ shares, which were down nearly 25% in Thursday morning trading on the New York Stock Exchange.
The acquisitions follow two deals involving mitral valve technologies it struck earlier this month.
In the latest moves, Edwards said it agreed to acquire JenaValve Technology, which is developing the first treatment for...
Today's Sponsors
Today's Sponsor